StemRIM
Status: Publicly traded
Direct answer
StemRIM is publicly traded on JPX under the ticker 4599.T.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy....
Can you invest in StemRIM?
Yes. StemRIM is publicly traded on JPX under the ticker 4599.T.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Detailed equity research is provided by MarketSnap.